SCHOTTS proficiency in both bioscience and US manufacturing will be increased by the acquisition of Applied Microarrays Inc (AMI).
A subdivision of SCHOTT, SCHOTT MINIFAB, has a long-term customer relationship with AMI. The branch is focused on making and producing microfluid devices for point-of-care and life sciences consumables. AMI’s extensive knowledge will add to SCHOTT’s potential to provide a manufacturing solution for sole source contracts.
“We pride ourselves on being an end-to-end partner for the global diagnostics industry. Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products“
Demand increases for point of care microarray consumables, particularly for identification of infectious disease, means that the purchase of AMI is crucial. This is because the acquisition notably adds to the biosensor printing potential of SCHOTT MINIFAB.
Head of SCHOTT MINIFAB, Greg Wolters, said “We pride ourselves on being an end-to-end partner for the global diagnostics industry. Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products. With the added bioscience knowledge of AMI, we become an even stronger partner, enhancing our capability in surface modification, functionalization and deposition for both glass and polymer products,”
Chief executive officer of AMI, Alastair Malcolm, said “We are joining SCHOTT at a time when the market continues to steer toward point-of-care diagnostics,” Our joint knowledge and technical capability allows us to offer a more holistic approach while shortening the time to market for customers.”
AMI is set to relocate to Arizona which will expand SCHOTT’s positioning of production and operation activities in the US, enabling it to better accommodate its customer base across the globe.